Drug Profile

F 230

Alternative Names: F-230

Latest Information Update: 17 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eisai Inc
Developer Gyre Therapeutics
Class Antihypertensives; Small molecules
Mechanism of Action Endothelin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Pulmonary arterial hypertension

Most Recent Events

10 Jun 2025 Phase-I clinical trials in Pulmonary arterial hypertension (In volunteers) in China (PO) (NCT06899815)
09 May 2025 Gyre Therapeutics plans to initiate a phase I trial for pulmonary arterial hypertension in China in Q2 2025 (NCT06899815)
30 May 2024 China’s National Medical Products Administration (NMPA) approves IND application for F 230 in Pulmonary arterial hypertension

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com